<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924285</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-PVC01</org_study_id>
    <nct_id>NCT02924285</nct_id>
  </id_info>
  <brief_title>Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease</brief_title>
  <acronym>CAT-PVC</acronym>
  <official_title>CAT-PVC Trial Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leipzig Heart Institute GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zentrum für Klinische Studien Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      For therapy of symptomatic premature ventricular complexes (PVCs) in subjects with structural&#xD;
      heart disease the current European Guidelines for the management of patients with ventricular&#xD;
      arrhythmias and the prevention of second cardiac death recommend catheter ablation as well as&#xD;
      amiodarone with a class IIa indication. Due to the lack of randomized data this study&#xD;
      investigates the comparison of catheter ablation and amiodarone for PVC treatment in patients&#xD;
      with structural heart disease. Therefore, patients will be randomized to one of two treatment&#xD;
      strategies: 1) catheter ablation, or 2) amiodarone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premature ventricular contractions (PVCs) are frequently encountered in patients with or&#xD;
      without structural heart disease. Even though PVCs in healthy subjects are considered to be a&#xD;
      benign arrhythmia. There is also evidence for the risk of a reversible cardiomyopathy due to&#xD;
      the PVC-induced inter- and intraventricular dyssynchrony. Data show that elimination of PVCs&#xD;
      by catheter ablation leads to an improvement of left ventricular dysfunction. In one-half of&#xD;
      the heart failure patients frequent PVCs occur with more than 1000/24 h. In patients with&#xD;
      structural heart disease premature ventricular contractions (PVCs) lead to an increased&#xD;
      mortality risk with only a burden of 10 PVC per hour. Further decreasing of left ventricular&#xD;
      function and worsening of heart failure are described. Therefore, therapy of frequent&#xD;
      monomorphic PVCs is recommended in these subjects. Beta-blockers as part of standard therapy&#xD;
      often remain ineffective or may lead to a paradoxic effect in patients with bradycardia. A&#xD;
      limiting factor for selection of antiarrhythmic drug due to increasing mortality is the&#xD;
      presence of structural heart disease. So in the most cases amiodarone is indicated. There are&#xD;
      data showing improvement of LV function after suppression of PVCs by amiodarone with a&#xD;
      significant reduction of the PVC burden in comparison to baseline. However, the adverse&#xD;
      effects of amiodarone are well-known especially in long-term therapy. On the other hand,&#xD;
      radiofrequency catheter ablation is a widely applied and safe treatment option for PVCs with&#xD;
      a high acute success rate of up to 90% PVC reduction in various circumstances like&#xD;
      pre-existing heart failure and post myocardial infarction subjects. Some small-sample studies&#xD;
      show the benefit of catheter ablation in subjects with depressed LV function. To date, there&#xD;
      are no randomized data for comparison of catheter ablation and amiodarone for therapy of PVCs&#xD;
      in patients with structural heart disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">March 4, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease</measure>
    <time_frame>Baseline and after 6 weeks</time_frame>
    <description>difference of the PVC burden in a 24 h Holter registration after 6 weeks and at baseline expressed as the amount of the baseline value ΔVES_r = (VES_6 - VES_0) / VES_0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (QoL) score according EQ-5D questionnaire</measure>
    <time_frame>Baseline, after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walking distance</measure>
    <time_frame>Baseline, after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>Baseline, after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum NT-proBNP level</measure>
    <time_frame>Baseline, after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) functional class</measure>
    <time_frame>Baseline, after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiovascular related hospitalization</measure>
    <time_frame>after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of drug adverse effects</measure>
    <time_frame>after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of procedure related complications</measure>
    <time_frame>after 6 weeks and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of the PVC burden in a 24 h Holter registration after 12 months and at baseline expressed as the amount of the baseline value</measure>
    <time_frame>Baseline and after 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Ventricular Premature Complexes</condition>
  <arm_group>
    <arm_group_label>Procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiofrequency catheter ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiarrhythmic Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiodarone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procedure (Radiofrequency catheter ablation)</intervention_name>
    <description>Radiofrequency catheter ablation</description>
    <arm_group_label>Procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:&#xD;
Antiarrhythmic Drug Amiodarone</description>
    <arm_group_label>Antiarrhythmic Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Structural heart disease with or without left ventricular dysfunction with&#xD;
&#xD;
          -  PVCs on Holter monitoring (burden &gt;10.000/d) AND/OR&#xD;
&#xD;
          -  PVCs on Holter monitoring correlating with symptoms AND/OR&#xD;
&#xD;
          -  Reduction of biventricular pacing &lt;92% in subjects with implanted cardiac&#xD;
             resynchronization therapy (CRT) device&#xD;
&#xD;
          -  Age: 18-87 years&#xD;
&#xD;
          -  Willing and capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ablation procedure or amiodarone for PVC without success&#xD;
&#xD;
          -  New York Heart Association (NYHA) functional class IV&#xD;
&#xD;
          -  Intracardial thrombus&#xD;
&#xD;
          -  Pulmonary fibrosis&#xD;
&#xD;
          -  Liver cirrhosis ≥ CHILD B&#xD;
&#xD;
          -  Manifest hyper- or hypothyreoidism&#xD;
&#xD;
          -  Long QT (QTc &gt; 500 ms if QRS&lt;120 ms, if QRS&gt;120 ms according to QTRR, QRS formula)&#xD;
&#xD;
          -  Sick sinus syndrome with symptomatic bradycardia &lt;55 bpm or AV node conduction delay&#xD;
             without implanted pacing device&#xD;
&#xD;
          -  Known side effects under amiodarone or iodine&#xD;
&#xD;
          -  Idiopathic angioedema&#xD;
&#xD;
          -  Comedication with known risk for torsade-de-pointes tachycardia&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Hindricks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

